Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 1/20 | 0.43 |
| ▸ | TBK1 | Q9UHD2 | 9/20 | 0.40 |
| ▸ | IKBKE | Q14164 | 1/20 | 0.40 |
| ▸ | FPR2 | P25090 | 2/20 | 0.39 |
| ▸ | PROKR1 | Q8TCW9 | 2/20 | 0.39 |
| ▸ | GPR6 | P46095 | 2/20 | 0.39 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1667168 | 0.84 | GPR119 (0.55) | TBK1IKBKE | |
| SCHEMBL12522329 | 0.83 | TBK1 (0.39) | EPHX2TBK1IKBKEFPR2PROKR1 | |
| SCHEMBL18818371 | 0.83 | XDH (0.47) | — | |
| SCHEMBL21723134 | 0.82 | EGFR (0.44) | EPHX2TBK1IKBKEGPR6 | |
| SCHEMBL4655923 | 0.82 | EPHX2 (0.56) | EPHX2GPR6 | |
| SCHEMBL16828572 | 0.82 | TBK1 (0.44) | TBK1 | |
| SCHEMBL16828738 | 0.82 | TBK1 (0.44) | TBK1 | |
| SCHEMBL18348317 | 0.80 | TBK1 (0.52) | TBK1IKBKE | |
| SCHEMBL24860958 | 0.80 | XDH (0.47) | TBK1IKBKE | |
| SCHEMBL15716135 | 0.80 | XDH (0.44) | TBK1IKBKES1PR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150352108-A1 | AMINO-PYRIMIDINE COMPOUNDS AS INHIBITORS OF TBK1 AND/OR IKK EPSILON | ALZHEIMER'S INSTITUTE OF AMERICA (US) | 2015-12-10 | — | — | US | disclosed |
| EP-2696683-A1 | COMPOSITIONS AND THERAPEUTIC USES OF IKK-RELATED KINASE EPSILON AND TANKBINDING KINASE 1 INHIBITORS | Alzheimer's Institute of America, Inc. (US) | 2014-02-19 | — | — | EP | disclosed |
| WO-2012142329-A1 | COMPOSITIONS AND THERAPEUTIC USES OF IKK-RELATED KINASE EPSILON AND TANKBINDING KINASE 1 INHIBITORS | MYREXIS, INC. (US) | 2012-10-18 | — | — | WO | disclosed |
| US-20120238540-A1 | AMINO-PYRIMIDINE COMPOUNDS AS INHIBITORS OF IKK EPSILON AND/OR TBK1 | MYREXIS, INC. (US) | 2012-09-20 | — | — | US | disclosed |
| EP-2488503-A1 | AMINO - PYRIMIDINE COMPOUNDS AS INHIBITORS OF TBKL AND/OR IKK EPSILON | Myrexis, Inc. (US) | 2012-08-22 | — | — | EP | disclosed |
| WO-2011046970-A1 | AMINO - PYRIMIDINE COMPOUNDS AS INHIBITORS OF TBKL AND/OR IKK EPSILON | MYREXIS, INC. (US) | 2011-04-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150352108-A1 | AMINO-PYRIMIDINE COMPOUNDS AS INHIBITORS OF TBK1 AND/OR IKK EPSILON | TBK1, NFKBIA, CHUK | EPHX2 2474/4885TBK1 1/4885IKBKE 9/4885 |
| US-20120238540-A1 | AMINO-PYRIMIDINE COMPOUNDS AS INHIBITORS OF IKK EPSILON AND/OR TBK1 | TBK1, NFKBIA, IKBKB | EPHX2 2974/4885TBK1 1/4885IKBKE 7/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.